MX2024009626A - Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr. - Google Patents

Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr.

Info

Publication number
MX2024009626A
MX2024009626A MX2024009626A MX2024009626A MX2024009626A MX 2024009626 A MX2024009626 A MX 2024009626A MX 2024009626 A MX2024009626 A MX 2024009626A MX 2024009626 A MX2024009626 A MX 2024009626A MX 2024009626 A MX2024009626 A MX 2024009626A
Authority
MX
Mexico
Prior art keywords
niraparib
prostate cancer
hrr
disorders
patients
Prior art date
Application number
MX2024009626A
Other languages
English (en)
Spanish (es)
Inventor
Ke Zhang
Peter Francis
Shibu Thomas
Angela Mennicke Lopez-Gitlitz
HUTNICK Natalie A
Gormley Michael P
Karen Ann Urtishak
Del Corral Adam A
Guilin Wang
Susan Xuemei Li
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2024009626A publication Critical patent/MX2024009626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024009626A 2022-02-04 2023-02-03 Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr. MX2024009626A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263306801P 2022-02-04 2022-02-04
EP22162765 2022-03-17
US202263330890P 2022-04-14 2022-04-14
US202263416200P 2022-10-14 2022-10-14
PCT/EP2023/052718 WO2023148345A1 (en) 2022-02-04 2023-02-03 Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations

Publications (1)

Publication Number Publication Date
MX2024009626A true MX2024009626A (es) 2024-08-09

Family

ID=85150948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009626A MX2024009626A (es) 2022-02-04 2023-02-03 Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr.

Country Status (8)

Country Link
US (1) US20250170146A1 (enExample)
EP (1) EP4472634A1 (enExample)
JP (1) JP2025506402A (enExample)
KR (1) KR20240148328A (enExample)
AU (1) AU2023214795A1 (enExample)
CA (1) CA3243120A1 (enExample)
MX (1) MX2024009626A (enExample)
WO (1) WO2023148345A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
DE60209673T2 (de) * 2002-10-22 2006-09-21 Rohm And Haas Co. Tablettenbeschichtung
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
EP2240466B1 (en) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20150246060A1 (en) * 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
BR112020015909A2 (pt) * 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
PH12022552093A1 (en) * 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
JP2023524794A (ja) * 2020-05-08 2023-06-13 ヤンセン ファーマシューティカ エヌ．ベー． アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置

Also Published As

Publication number Publication date
CA3243120A1 (en) 2023-08-10
US20250170146A1 (en) 2025-05-29
WO2023148345A1 (en) 2023-08-10
JP2025506402A (ja) 2025-03-11
KR20240148328A (ko) 2024-10-11
AU2023214795A1 (en) 2024-09-19
EP4472634A1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
Combs et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients
Bishop et al. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?
Corkum et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial
Badiyan et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies
Poulsen et al. Factors influencing relapse-free survival in Merkel cell carcinoma of the lower limb—a review of 60 cases
Webb et al. Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer
Yu et al. Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer
Griffiths et al. Using advanced wound care and hyperbaric oxygen to manage wound complications following treatment of vulvovaginal carcinoma
Topkan et al. Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy
Martin What is the optimal interval between chemoradiation and esophagectomy?
Blanco et al. Brachytherapy in localized prostate cancer with or without androgen deprivation
Liao et al. 140 Rising incidence of cervical adenocarcinoma in the United States–who is most at risk?
RU2548506C1 (ru) Способ восстановительного лечения онкогинекологических больных репродуктивного возраста раком тела и шейки матки после проведенного противоопухолевого лечения
Geller et al. Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: an observational study
Shiryaev et al. A method for intra-percardial PDT for malignant mesothelioma
Naumann et al. 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)
YAHŞİ et al. MEME KORUYUCU CERRAHI SONRASI (MKC) SIMULTANE İNTEGRE BOOST (SIB) TEKNIĞININ FARKLILIĞI
Carreras et al. Prior, synchronous and metachronous malignancies in patients with head and neck cancer
Fonseca et al. Impact of the COVID-19 pandemic on surgical treatment of colon cancer in a University Hospital
Qi et al. Radiotherapy of the Primary Tumor and All Metastatic Lesions in Oligometastatic Prostate Cancer
RU2666694C1 (ru) Способ лечения низкорасположенных опухолей прямой кишки и анального канала
Ravi et al. 91 LONG TERM OUTCOMES AND RECURRENCE PATTERN FOLLOWING ACCELERATED PARTIAL BREAST IRRADIATION USING MAMMOSITE
Wilkinson et al. OC-92 IMPACT OF MARGIN STATUS AFTER APBI: AN ANALYSIS OF THE AMERICAN SOCIETY OF BREAST SURGEONS MAMMOSITEEE REGISTRY TRIAL
Daugherty et al. (P08) Retrospective Comparison of Gammaknife Radiosurgery and Hypofractionated Radiotherapy as Treatment Options for Intracranial Metastases Measuring 4cc or Larger
Kaufman et al. Association between tumour lesion size and health-related quality of life outcomes in patients with metastatic Merkel cell carcinoma treated with Avelumab